EGFR Clinical Trials
0 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR
Allist Pharmaceuticals, Inc.300 enrolled2 locationsNCT06956001
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 1
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
Advanced Solid TumorCancerNSCLC+5 more
TOLREMO therapeutics AG50 enrolled7 locationsNCT06403436
Recruiting
Phase 2
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NSCLCEGFRAdjuvant Drug Therapy
Betta Pharmaceuticals Co., Ltd.28 enrolled2 locationsNCT07181499
Recruiting
Phase 2
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
EGFR
Peng Zhang60 enrolled1 locationNCT06755684